Abstract
About 30 % of patients receiving PDE5-Inhibitors for the treatment of erectile dysfunction do not respond to oral drug. It could depend on lack of correct information for drug use, lack of appropriate follow-up, presence of comorbidities, unrealistic patient expectations, incorrect diagnosis, performance anxiety and problematic relationships. So, before prescribing to patients a second line therapy, it is mandatory to carefully check if patient is taking PDE5-inhibitors in the right way and with an adequate sexual stimulation, if the medication taken is a licensed one, if patient is affected by hypogonadism and therefore needs a testosterone replacement therapy or if patient could benefit from the treatment of comorbidities. In addition, switching to another PDE5-inhibitor or a combination therapy with long-acting and short-acting PDE5-inhibitors could be effective strategies in non-responders. If patients are still not-responders, a second line therapy could be suggested. Intracavernosal injections (ICI) with vasoactive agents (prostaglandins, papaverine, phentolamine, vasoactive intestinal polypeptide) are the most widely used second line therapy and their effectiveness is high (>70 %). Nevertheless, the drop-out rate of these therapy is still high due to willing of a definitive and permanent therapy, discomfort in self-injection, lack of spontaneity in sexual relationship and stop of sexual activity. Use of vacuum device is a valid treatment too for erectile dysfunction with a success rate of more than 90 % and could be an alternative method in older patients in a stable relationship. Treatment with alprostadil cream with a permeation enhancer in patients affected by erectile dysfunction of all etiology and physical therapy with low-intensity shockwave in patients affected by vasculogenic erectile dysfunction are very promising strategies but to date no specific recommendation could be given for their use. Combination of different second line therapies or combination between a second line treatment and a PDE5-inhibitor could be tried before proposing a penile prosthesis implant.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
References
Feldman HA, Goldstein I, Hatzichristou DG, Krane RJ, McKinlay JB. Impotence and its medical and psychosocial correlates: results of the Massachusetts Male Aging Study. J Urol. 1994;151(1):54–61.
Johannes CB, et al. Incidence of erectile dysfunction in men 40 to 69 years old: longitudinal results from the Massachusetts male aging study. J Urol. 2000;163(2):460–3.
Capogrosso P, et al. One patient out of four with newly diagnosed erectile dysfunction is a young man--worrisome picture from the everyday clinical practice. J Sex Med. 2013;10(7):1833–41.
Mirone V, Gentile V, Zizzo G, Terry M, Longo N, Fusco F, Parazzini F. Did men with erectile dysfunction discuss their condition with partner and physicians? A survey of men attending a free call information service. Int J Impot Res. 2002;14(4):256–8.
Hatzimouratidis K, Hatzichristou DG. A comparative review of the options for treatment of erectile dysfunction: which treatment for which patient? Drugs. 2005;65:1621–50.
Hatzichristou DG. Sildenafil citrate: lessons learned from 3 years of clinical experience. Int J Impot Res. 2002;14 Suppl 1:S43–52.
Hatzimouratidis K, Moysidis K, Bekos A, Tsimtsiou Z, Ioannidis E, Hatzichristou D. Treatment strategy for “non-responders” to tadalafil and vardenafil: a real-life study. Eur Urol. 2006;50(1):126–32.
Debruyne FM, et al. Time to onset of action of vardenafil: a retrospective analysis of the pivotal trials for the orodispersible and film-coated tablet formulations. J Sex Med. 2011;8(10):2912–23.
Forgue ST, et al. Tadalafil pharmacokinetics in healthy subjects. Br J Clin Pharmacol. 2006;61(3):280–8.
Moncada I, et al. Efficacy of sildenafil citrate at 12 hours after dosing: re-exploring the therapeutic window. Eur Urol. 2004;46(3):357–60; discussion 360–1.
Gandaglia G, et al. A systematic review of the association between erectile dysfunction and cardiovascular disease. Eur Urol. 2014;65(5):968–78.
McCullough AR, et al. Achieving treatment optimization with sildenafil citrate (Viagra) in patients with erectile dysfunction. Urology. 2002;60(2 Suppl 2):28–38.
Campbell N, Clark JP, Stecher VJ, Goldstein I. Internet-ordered viagra (sildenafil citrate) is rarely genuine. J Sex Med. 2012;9(11):2943–51.
Buvat J, Montorsi F, Maggi M, Porst H, Kaipia A, Colson MH, Cuzin B, Moncada I, Martin-Morales A, Yassin A, Meuleman E, Eardley I, Dean JD, Shabsigh R. Hypogonadal men nonresponders to the PDE5 inhibitor tadalafil benefit from normalization of testosterone levels with a 1 % hydroalcoholic testosterone gel in the treatment of erectile dysfunction (TADTEST study). J Sex Med. 2011;8(1):284–93.
Eardley I, et al. Factors associated with preference for sildenafil citrate and tadalafil for treating erectile dysfunction in men naive to phosphodiesterase 5 inhibitor therapy: post hoc analysis of data from a multicentre, randomized, open-label, crossover study. BJU Int. 2007;100(1):122–9.
Cui H, et al. Efficacy and safety of long-term tadalafil 5 mg once daily combined with sildenafil 50 mg as needed at the early stage of treatment for patients with erectile dysfunction. Andrologia. 2015;47(1):20–4.
Lakin MM, et al. Intracavernous injection therapy: analysis of results and complications. J Urol. 1990;143(6):1138–41.
Lin JS, Lin YM, Jou YC, Cheng JT. Role of cyclic adenosine monophosphate in prostaglandin E1-induced penile erection in rabbits. Eur Urol. 1995;28:259–65.
Kifor I, Williams GH, Vickers MA, Sullivan MP, Jodbert P, Dluhy RG. Tissue angiotensin II as a modulator of erectile function. I. Angiotensin peptide content, secretion and effects in the corpus cavernosum. J Urol. 1997;157:1920–5.
Molderings GJ, van Ahlen H, Gothert M. Modulation of noradrenaline release in human corpus cavernosum by presynaptic prostaglandin receptors. Int J Impot Res. 1992;4:19–25.
Porst H, Buvat J, Meuleman E, Michal V, Wagner G. Intracavernous Alprostadil Alfadex an effective and well tolerated treatment for erectile dysfunction. Result of a long term European study. Int J Impot Res. 1998;10:225–31.
Porst H, et al. SOP conservative (medical and mechanical) treatment of erectile dysfunction. J Sex Med. 2013;10(1):130–71.
Dinsmore WW, et al. Vasoactive intestinal polypeptide/phentolamine for intracavernosal injection in erectile dysfunction. BJU Int. 2008;102(8):933–7.
Padma-Nathan H, et al. Treatment of men with erectile dysfunction with transurethral alprostadil. Medicated Urethral System for Erection (MUSE) Study Group. N Engl J Med. 1997;336(1):1–7.
Nehra A, Blute ML, Barrett DM, Moreland RB. Rationale for combination therapy of intraurethral prostaglandin E(1) and sildenafil in the salvage of erectile dysfunction patients desiring noninvasive therapy. Int J Impot Res. 2002;14 Suppl 1:S38–42.
Yeager J, et al. Retention and migration of alprostadil cream applied topically to the glans meatus for erectile dysfunction. Int J Impot Res. 2005;17(1):91–5.
Moncada I, Cuzin B. Clinical efficacy and safety of Vitaros©/Virirec© (Alprostadil cream) for the treatment of erectile dysfunction. Urologia. 2015;82(2):84–92.
Meier-Davis SR, Debar S, Siddoway J, Rabe M. Daily application of alprostadil topical cream (Vitaros) does not impact vaginal pH, flora, or histology in female cynomolgus monkeys. Int J Toxicol. 2015;34(1):11–5.
Levine LA, et al. Vacuum constriction and external erection devices in erectile dysfunction. Urol Clin North Am. 2001;28(2):335–41, ix–x.
Yuan J, et al. Vacuum therapy in erectile dysfunction – science and clinical evidence. Int J Impot Res. 2010;22(4):211–9.
Vardi Y, Appel B, Jacob G, Massarwi O, Gruenwald I. Can low-intensity extracorporeal shockwave therapy improve erectile function? A 6-month follow-up pilot study in patients with organic erectile dysfunction. Eur Urol. 2010;58:243–8.
Gruenwald I, Appel B, Vardi Y. Low-intensity extracorporeal shock wave therapy – a novel effective treatment for erectile dysfunction in severe ED patients who respond poorly to PDE5 inhibitor therapy. J Sex Med. 2012;9:259–64.
Olsen AB, Persiani M, Boie S, Hanna M, Lund L. Can low-intensity extracorporeal shockwave therapy improve erectile dysfunction? A prospective, randomized, double-blind, placebo-controlled study. Scand J Urol. 2015;49(4):329–33.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2017 Springer-Verlag London
About this chapter
Cite this chapter
Arcaniolo, D., Autorino, R., Balsamo, R., De Sio, M. (2017). Optimum Use of Second Line Treatment Options for Erectile Dysfunction. In: Rané, A., Turna, B., Autorino, R., Rassweiler, J. (eds) Practical Tips in Urology. Springer, London. https://doi.org/10.1007/978-1-4471-4348-2_17
Download citation
DOI: https://doi.org/10.1007/978-1-4471-4348-2_17
Published:
Publisher Name: Springer, London
Print ISBN: 978-1-4471-4347-5
Online ISBN: 978-1-4471-4348-2
eBook Packages: MedicineMedicine (R0)